atypical ductal hyperplasia of breast
Jump to navigation
Jump to search
Epidemiology
- 100,000 women per year in the U.S[3]
Radiology
- stereotactic biopsy of suspicious microcalcifications identified at mammography
Complications
- 3-5 fold increased risk of breast cancer
- cumulative incidence of breast cancer at 30 years is 35%[1][2]
- 10 year risk for invasive breast cancer after diagnosis is 5.0-6.7%[3]
Differential diagnosis
Management
- exemestane reduces risk of breast cancer in post-menopausal women with atypical ductal hyperplasia[1][2]
More general terms
Additional terms
References
- ↑ 1.0 1.1 1.2 Medical Knowledge Self Assessment Program (MKSAP) 17, 19. American College of Physicians, Philadelphia 2015, 2021.
- ↑ 2.0 2.1 2.2 Goss PE et al Exemestane for Breast-Cancer Prevention in Postmenopausal Women N Engl J Med. 2011 Jun 23;364(25):2381-91. Epub 2011 Jun 4. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21639806
- ↑ 3.0 3.1 3.2 Menes TS et al. Subsequent breast cancer risk following diagnosis of atypical ductal hyperplasia on needle biopsy. JAMA Oncol 2016 Sep 8; PMID: https://www.ncbi.nlm.nih.gov/pubmed/27607465
Howard-McNatt M. Atypical ductal hyperplasia: What is the current risk for developing breast cancer? JAMA Oncol 2016 Sep 8; PMID: https://www.ncbi.nlm.nih.gov/pubmed/27606772